The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.

A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.

Analysts’ fears have been confirmed as a US FDA demand for clinical outcomes data has forced Applied Therapeutics to delay a planned filing for its lead product candidate, AT-007, in the rare disease galactosemia based on biomarker data alone.